Adrian Vella

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Adrian Vella sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 7 completed top decile by trial count

Adrian Vella: 9 sponsored US clinical trials, 1 recruiting.

Adrian Vella sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 4 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 3 trials.

Top-decile sponsor footprint

Adrian Vella ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2

The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

NCT05499702
ACTIVE NOT RECRUITING Phase 1

The Effects of Glucagon on Hepatic Metabolism

NCT05500586
COMPLETED Phase 3

A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics

NCT04466566
COMPLETED Phase 3

Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

NCT04466618
COMPLETED Phase 3

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

NCT04459338
COMPLETED Phase 3

The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans

NCT04461015
COMPLETED Early Phase 1

The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass

NCT01843881
COMPLETED Early Phase 1

The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass

NCT01843855
COMPLETED Phase 1

Dose-response Study of Exendin-9,39 on Glucose Metabolism

NCT01218633

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1
Phase 3 4

Therapeutic Areas

Healthy 3
Type 2 Diabetes 2
Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1 1
NAFLD 1
Type 2 Diabetes Mellitus 1
Obesity 1

What is open in the Adrian Vella pipeline

1 recruiting of 9 indexed (11% open); 7 completed (78%).

Phase mix: 4 late (III/IV) vs 5 early (I/II) (balanced across stages).

Top condition: Healthy (3 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Adrian Vella: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Adrian Vella sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Adrian Vella4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.AIDS Malignancy ConsortiumAmylyx PharmaceuticalsAprea Therapeutics
Adrian Vella sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Adrian Vella sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Adrian Vella page

9 registered trials is a research-attention snapshot, not an endorsement of Adrian Vella or any single study.

  • 1 of Adrian Vella's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition Adrian Vella studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Adrian Vella pipeline card: 9 registered trials from official public datasets.Report a data error.